                                SEQUENCE LISTING

<110> Dimitrov, Dimiter S.
      Feng, Yang
      The Government of the United States of America
         as represented by The Secretary of the
         Department of Health and Human Services

<120> Anti-DR4 Agonist Antibodies
  

<130> 77867-808141

<140> WO Not yet assigned 
<141> Not yet assigned  

<150> US 61/355,349       
<151> 2010-06-16  

<160> 40

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 216
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 light
      chain variable region

<400> 1
Gln Pro Val Leu Thr Gln Pro Pro Ser Ala Ser Ala Thr Pro Gly Gln
 1               5                  10                  15      
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
            20                  25                  30          
Thr Leu Asp Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
        35                  40                  45              
Ile Phe Asp Thr Asn Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
    50                  55                  60                  
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65                  70                  75                  80  
Ala Glu Asp Glu Ala Val Tyr Phe Cys Ala Thr Trp Asp Asn Ser Leu
                85                  90                  95      
Asn Gly Ala Val Phe Gly Gly Gly Thr Lys Leu Ser Val Pro Arg Gln
            100                 105                 110         
Ala Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu Glu
        115                 120                 125             
Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe Tyr
    130                 135                 140                 
Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val Lys
145                 150                 155                 160 
Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys Tyr
                165                 170                 175     
Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser His
            180                 185                 190         
Arg Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu Lys
        195                 200                 205             
Thr Val Ala Pro Thr Glu Cys Ser
    210                 215     


<210> 2
<211> 240
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 heavy
      chain variable region

<400> 2
Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1               5                  10                  15      
Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn
            20                  25                  30          
Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu
        35                  40                  45              
Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala
    50                  55                  60                  
Val Ser Val Lys Gly Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn
65                  70                  75                  80  
Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val
                85                  90                  95      
Tyr Tyr Cys Ala Arg Asp Leu Gly Val Ala Ala Ala Asp Ser Tyr Tyr
            100                 105                 110         
Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser
        115                 120                 125             
Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser
    130                 135                 140                 
Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp
145                 150                 155                 160 
Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr
                165                 170                 175     
Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr
            180                 185                 190         
Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln
        195                 200                 205             
Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp
    210                 215                 220                 
Lys Lys Val Gly Pro Lys Ser Cys Asp Lys Thr Ser Gly Gln Ala Gly
225                 230                 235                 240 


<210> 3
<211> 217
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M922 light
      chain variable region

<400> 3
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
 1               5                  10                  15      
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
            20                  25                  30          
Thr Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
        35                  40                  45              
Ile Tyr Ser Asn Asn Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
    50                  55                  60                  
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65                  70                  75                  80  
Ser Glu Asp Glu Ala Asp Tyr Tyr Cys Ala Ala Trp Asp Asp Ser Leu
                85                  90                  95      
Asn Gly Arg Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
            100                 105                 110         
Gln Pro Lys Ala Ala Pro Ser Val Thr Leu Phe Pro Pro Ser Ser Glu
        115                 120                 125             
Glu Leu Gln Ala Asn Lys Ala Thr Leu Val Cys Leu Ile Ser Asp Phe
    130                 135                 140                 
Tyr Pro Gly Ala Val Thr Val Ala Trp Lys Ala Asp Ser Ser Pro Val
145                 150                 155                 160 
Lys Ala Gly Val Glu Thr Thr Thr Pro Ser Lys Gln Ser Asn Asn Lys
                165                 170                 175     
Tyr Ala Ala Ser Ser Tyr Leu Ser Leu Thr Pro Glu Gln Trp Lys Ser
            180                 185                 190         
His Lys Ser Tyr Ser Cys Gln Val Thr His Glu Gly Ser Thr Val Glu
        195                 200                 205             
Lys Thr Val Ala Pro Thr Glu Cys Ser
    210                 215         


<210> 4
<211> 233
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M922 heavy
      chain variable region

<400> 4
Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1               5                  10                  15      
Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn
            20                  25                  30          
Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu
        35                  40                  45              
Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala
    50                  55                  60                  
Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn
65                  70                  75                  80  
Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val
                85                  90                  95      
Tyr Tyr Cys Ala Arg Glu Thr Val Ala Val Asp Ala Phe Asp Ile Trp
            100                 105                 110         
Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro
        115                 120                 125             
Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr
    130                 135                 140                 
Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr
145                 150                 155                 160 
Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro
                165                 170                 175     
Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr
            180                 185                 190         
Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Ser Val Asn
        195                 200                 205             
His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser
    210                 215                 220                 
Cys Asp Lys Thr Ser Gly Gln Ala Gly
225                 230             


<210> 5
<211> 8
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921and
      M922 light chain CDR1

<400> 5
Ser Ser Asn Ile Gly Ser Asn Thr
 1               5              


<210> 6
<211> 3
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 light
      chain CDR2

<400> 6
Asp Thr Asn
 1          


<210> 7
<211> 12
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 light
      chain CDR3

<400> 7
Ala Thr Trp Asp Asn Ser Leu Asn Gly Ala Val Phe
 1               5                  10          


<210> 8
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 and
      M922 heavy chain CDR1

<400> 8
Gly Asp Ser Val Ser Ser Asn Ser Ala Ala
 1               5                  10  


<210> 9
<211> 9
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 and
      M922 heavy chain CDR2

<400> 9
Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn
 1               5                  


<210> 10
<211> 20
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 heavy
      chain CDR3

<400> 10
Ala Arg Asp Leu Gly Val Ala Ala Ala Asp Ser Tyr Tyr Tyr Tyr Gly
 1               5                  10                  15      
Met Asp Val Trp
            20  


<210> 11
<211> 3
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M922 light
      chain CDR2

<400> 11
Ser Asn Asn
 1          


<210> 12
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M922 light
      chain CDR3

<400> 12
Ala Ala Trp Asp Asp Ser Leu Asn Gly Arg Val Val Phe
 1               5                  10              


<210> 13
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M922 heavy
      chain CDR3

<400> 13
Ala Arg Glu Thr Val Ala Val Asp Ala Phe Asp Ile Trp
 1               5                  10              


<210> 14
<211> 25
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 light
      chain FR1

<400> 14
Gln Pro Val Leu Thr Gln Pro Pro Ser Ala Ser Ala Thr Pro Gly Gln
 1               5                  10                  15      
Arg Val Thr Ile Ser Cys Ser Gly Ser
            20                  25  


<210> 15
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 light
      chain FR2

<400> 15
Leu Asp Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile
 1               5                  10                  15      
Phe
    

<210> 16
<211> 36
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 light
      chain FR3

<400> 16
Arg Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly
 1               5                  10                  15      
Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala
            20                  25                  30          
Val Tyr Phe Cys
        35      


<210> 17
<211> 10
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 light
      chain FR4

<400> 17
Gly Gly Gly Thr Lys Leu Ser Val Pro Arg
 1               5                  10  


<210> 18
<211> 25
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 and
      M922 heavy chain FR1

<400> 18
Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1               5                  10                  15      
Thr Leu Ser Leu Thr Cys Ala Ile Ser
            20                  25  


<210> 19
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 and
      M922 heavy chain FR2

<400> 19
Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu Trp Leu Gly
 1               5                  10                  15      
Arg
    

<210> 20
<211> 38
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 heavy
      chain FR3

<400> 20
Asp Tyr Ala Val Ser Val Lys Gly Arg Ile Thr Ile Asn Pro Asp Thr
 1               5                  10                  15      
Ser Lys Asn Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp
            20                  25                  30          
Thr Ala Val Tyr Tyr Cys
        35              


<210> 21
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 heavy
      chain FR4

<400> 21
Gly Gln Gly Thr Thr Val Thr Val Ser Ser Ala
 1               5                  10      


<210> 22
<211> 25
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M922 light
      chain FR1

<400> 22
Gln Ser Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln
 1               5                  10                  15      
Arg Val Thr Ile Ser Cys Ser Gly Ser
            20                  25  


<210> 23
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M922 light
      chain FR2

<400> 23
Val Asn Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile
 1               5                  10                  15      
Tyr
    

<210> 24
<211> 36
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M922 light
      chain FR3

<400> 24
Gln Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly
 1               5                  10                  15      
Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Ser Glu Asp Glu Ala
            20                  25                  30          
Asp Tyr Tyr Cys
        35      


<210> 25
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M922 light
      chain FR4

<400> 25
Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
 1               5                  10      


<210> 26
<211> 38
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M922 heavy
      chain FR3

<400> 26
Asp Tyr Ala Val Ser Val Lys Ser Arg Ile Thr Ile Asn Pro Asp Thr
 1               5                  10                  15      
Ser Lys Asn Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp
            20                  25                  30          
Thr Ala Val Tyr Tyr Cys
        35              


<210> 27
<211> 11
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M922 heavy
      chain FR4

<400> 27
Gly Gln Gly Thr Met Val Thr Val Ser Ser Ala
 1               5                  10      


<210> 28
<211> 17
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody light chain
      FR2 consensus sequence

<220> 
<221> VARIANT        
<222> (1)...(1)
<223> Xaa = Leu or Val

<220> 
<221> VARIANT        
<222> (17)...(17)
<223> Xaa = Phe or Tyr

<400> 28
Xaa Asx Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Ile
 1               5                  10                  15      
Xaa
    

<210> 29
<211> 36
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody light chain
      FR3 consensus sequence

<220> 
<221> VARIANT        
<222> (1)...(1)
<223> Xaa = Arg or Gln

<220> 
<221> VARIANT        
<222> (28)...(28)
<223> Xaa = Ala or Ser

<220> 
<221> VARIANT        
<222> (33)...(33)
<223> Xaa = Val or Asp

<220> 
<221> VARIANT        
<222> (35)...(35)
<223> Xaa = Phe or Tyr

<400> 29
Xaa Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly
 1               5                  10                  15      
Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln Xaa Glu Asp Glu Ala
            20                  25                  30          
Xaa Tyr Xaa Cys
        35      


<210> 30
<211> 38
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody heavy chain
      FR3 consensus sequence

<220> 
<221> VARIANT        
<222> (8)...(8)
<223> Xaa = Ser or Gly

<400> 30
Asp Tyr Ala Val Ser Val Lys Xaa Arg Ile Thr Ile Asn Pro Asp Thr
 1               5                  10                  15      
Ser Lys Asn Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp
            20                  25                  30          
Thr Ala Val Tyr Tyr Cys
        35              


<210> 31
<211> 3
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody light chain
      CDR2 consensus sequence

<220> 
<221> VARIANT        
<222> (1)...(1)
<223> Xaa = Asp or Ser

<220> 
<221> VARIANT        
<222> (2)...(2)
<223> Xaa = Asn or Thr

<400> 31
Xaa Xaa Asn
 1          


<210> 32
<211> 13
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody light chain
      CDR3 consensus sequence

<220> 
<221> VARIANT        
<222> (2)...(2)
<223> Xaa = Ala or Thr

<220> 
<221> VARIANT        
<222> (10)...(10)
<223> Xaa = Ala or Arg

<220> 
<221> VARIANT        
<222> (12)...(12)
<223> Xaa = Val or absent

<400> 32
Ala Xaa Trp Asp Asx Ser Leu Asn Gly Xaa Val Xaa Phe
 1               5                  10              


<210> 33
<211> 89
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody light chain
      variable segment (FR1-CDR1-FR2-CDR2-FR3) consensus
      sequence

<220> 
<221> VARIANT        
<222> (2)...(2)
<223> Xaa = Pro or Ser

<220> 
<221> VARIANT        
<222> (12)...(12)
<223> Xaa = Ala or Gly

<220> 
<221> VARIANT        
<222> (34)...(34)
<223> Xaa = Leu or Val

<220> 
<221> VARIANT        
<222> (50)...(50)
<223> Xaa = Phe or Tyr

<220> 
<221> VARIANT        
<222> (51)...(51)
<223> Xaa = Asp or Ser

<220> 
<221> VARIANT        
<222> (52)...(52)
<223> Xaa = Ser or Thr

<220> 
<221> VARIANT        
<222> (54)...(54)
<223> Xaa = Arg or Gln

<220> 
<221> VARIANT        
<222> (81)...(81)
<223> Xaa = Ala or Ser

<220> 
<221> VARIANT        
<222> (86)...(86)
<223> Xaa = Asp or Val

<220> 
<221> VARIANT        
<222> (88)...(88)
<223> Xaa = Phe or Tyr

<400> 33
Gln Xaa Val Leu Thr Gln Pro Pro Ser Ala Ser Xaa Thr Pro Gly Gln
 1               5                  10                  15      
Arg Val Thr Ile Ser Cys Ser Gly Ser Ser Ser Asn Ile Gly Ser Asn
            20                  25                  30          
Thr Xaa Asp Trp Phe Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu
        35                  40                  45              
Ile Xaa Xaa Xaa Asn Xaa Arg Pro Ser Gly Val Pro Asp Arg Phe Ser
    50                  55                  60                  
Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Gln
65                  70                  75                  80  
Xaa Glu Asp Glu Ala Xaa Tyr Xaa Cys
                85                  


<210> 34
<211> 99
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody heavy chain
      variable segment (FR1-CDR1-FR2-CDR2-FR3) consensus
      sequence

<220> 
<221> VARIANT        
<222> (69)...(69)
<223> Xaa = Ser or Gly

<400> 34
Gln Val Gln Leu Gln Gln Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
 1               5                  10                  15      
Thr Leu Ser Leu Thr Cys Ala Ile Ser Gly Asp Ser Val Ser Ser Asn
            20                  25                  30          
Ser Ala Ala Trp Asn Trp Ile Arg Gln Ser Pro Ser Arg Gly Leu Glu
        35                  40                  45              
Trp Leu Gly Arg Thr Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala
    50                  55                  60                  
Val Ser Val Lys Xaa Arg Ile Thr Ile Asn Pro Asp Thr Ser Lys Asn
65                  70                  75                  80  
Gln Phe Ser Leu Gln Leu Asn Ser Val Thr Pro Glu Asp Thr Ala Val
                85                  90                  95      
Tyr Tyr Cys
            

<210> 35
<211> 468
<212> PRT
<213> Homo sapiens

<220> 
<223> human death receptor 4 (DR4), tumor necrosis factor-related
      apoptosis-inducing ligand receptor 1 (TRAIL-R1, TRAIL receptor
      1), cytotoxic TRAIL receptor, tumor necrosis factor receptor
      superfamily member 10A (TNFRSF10A) precursor, APO2, CD261

<400> 35
Met Ala Pro Pro Pro Ala Arg Val His Leu Gly Ala Phe Leu Ala Val
 1               5                  10                  15      
Thr Pro Asn Pro Gly Ser Ala Ala Ser Gly Thr Glu Ala Ala Ala Ala
            20                  25                  30          
Thr Pro Ser Lys Val Trp Gly Ser Ser Ala Gly Arg Ile Glu Pro Arg
        35                  40                  45              
Gly Gly Gly Arg Gly Ala Leu Pro Thr Ser Met Gly Gln His Gly Pro
    50                  55                  60                  
Ser Ala Arg Ala Arg Ala Gly Arg Ala Pro Gly Pro Arg Pro Ala Arg
65                  70                  75                  80  
Glu Ala Ser Pro Arg Leu Arg Val His Lys Thr Phe Lys Phe Val Val
                85                  90                  95      
Val Gly Val Leu Leu Gln Val Val Pro Ser Ser Ala Ala Thr Ile Lys
            100                 105                 110         
Leu His Asp Gln Ser Ile Gly Thr Gln Gln Trp Glu His Ser Pro Leu
        115                 120                 125             
Gly Glu Leu Cys Pro Pro Gly Ser His Arg Ser Glu His Pro Gly Ala
    130                 135                 140                 
Cys Asn Arg Cys Thr Glu Gly Val Gly Tyr Thr Asn Ala Ser Asn Asn
145                 150                 155                 160 
Leu Phe Ala Cys Leu Pro Cys Thr Ala Cys Lys Ser Asp Glu Glu Glu
                165                 170                 175     
Arg Ser Pro Cys Thr Thr Thr Arg Asn Thr Ala Cys Gln Cys Lys Pro
            180                 185                 190         
Gly Thr Phe Arg Asn Asp Asn Ser Ala Glu Met Cys Arg Lys Cys Ser
        195                 200                 205             
Arg Gly Cys Pro Arg Gly Met Val Lys Val Lys Asp Cys Thr Pro Trp
    210                 215                 220                 
Ser Asp Ile Glu Cys Val His Lys Glu Ser Gly Asn Gly His Asn Ile
225                 230                 235                 240 
Trp Val Ile Leu Val Val Thr Leu Val Val Pro Leu Leu Leu Val Ala
                245                 250                 255     
Val Leu Ile Val Cys Cys Cys Ile Gly Ser Gly Cys Gly Gly Asp Pro
            260                 265                 270         
Lys Cys Met Asp Arg Val Cys Phe Trp Arg Leu Gly Leu Leu Arg Gly
        275                 280                 285             
Pro Gly Ala Glu Asp Asn Ala His Asn Glu Ile Leu Ser Asn Ala Asp
    290                 295                 300                 
Ser Leu Ser Thr Phe Val Ser Glu Gln Gln Met Glu Ser Gln Glu Pro
305                 310                 315                 320 
Ala Asp Leu Thr Gly Val Thr Val Gln Ser Pro Gly Glu Ala Gln Cys
                325                 330                 335     
Leu Leu Gly Pro Ala Glu Ala Glu Gly Ser Gln Arg Arg Arg Leu Leu
            340                 345                 350         
Val Pro Ala Asn Gly Ala Asp Pro Thr Glu Thr Leu Met Leu Phe Phe
        355                 360                 365             
Asp Lys Phe Ala Asn Ile Val Pro Phe Asp Ser Trp Asp Gln Leu Met
    370                 375                 380                 
Arg Gln Leu Asp Leu Thr Lys Asn Glu Ile Asp Val Val Arg Ala Gly
385                 390                 395                 400 
Thr Ala Gly Pro Gly Asp Ala Leu Tyr Ala Met Leu Met Lys Trp Val
                405                 410                 415     
Asn Lys Thr Gly Arg Asn Ala Ser Ile His Thr Leu Leu Asp Ala Leu
            420                 425                 430         
Glu Arg Met Glu Glu Arg His Ala Arg Glu Lys Ile Gln Asp Leu Leu
        435                 440                 445             
Val Asp Ser Gly Lys Phe Ile Tyr Leu Glu Asp Gly Thr Gly Ser Ala
    450                 455                 460                 
Val Ser Leu Glu
465             


<210> 36
<211> 649
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 light
      chain

<400> 36
cagcctgtgc tgactcagcc accctcagcg tctgcgaccc ccggacagag ggtcaccatc 60
tcttgctctg gaagcagttc caacatcgga agtaatactt tagactggtt ccagcagctc 120
ccaggaacgg cccccaaact cctcatcttt gatactaatc ggcggccctc aggggtccct 180
gaccgattct ctggctccaa gtctggcacc tcagcctccc tggccatcag tggcctccag 240
gctgaggatg aggctgttta cttttgtgca acatgggata acagcctcaa cggcgcggtg 300
ttcggcgggg gtaccaagct cagcgtccca cgtcaggcca aggctgcccc ctcggtcact 360
ctgttcccgc cctcctctga ggagcttcaa gccaacaagg ccacactggt gtgtctcata 420
agtgacttct acccgggagc cgtgacagtg gcctggaagg cagatagcag ccccgtcaag 480
gcgggagtgg agaccaccac accctccaaa caaagcaaca acaagtacgc ggccagcagc 540
tatctgagcc tgacgcctga gcagtggaag tcccacagaa gctacagctg ccaggtcacg 600
catgaaggga gcaccgtgga gaagacagtg gcccctacag aatgttcat             649

<210> 37
<211> 720
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M921 heavy
      chain

<400> 37
caggtacagc tgcagcagtc aggtccagga ctggtgaagc cctcgcagac cctctcactc 60
acctgtgcca tctccgggga cagtgtctct agcaacagtg ctgcttggaa ctggatcagg 120
cagtccccat cgagaggcct tgagtggctg ggaaggacat actacaggtc caagtggtat 180
aatgattatg cagtatctgt gaaaggtcga ataaccatca acccagacac atccaagaac 240
cagttctccc tgcagctgaa ctctgtgact cccgaggaca cggctgtgta ttactgtgca 300
agagacttgg gagtagcagc agctgacagc tactactact acggtatgga cgtctggggc 360
caagggacca cggtcaccgt ctcctcagcc tccaccaagg gcccatcggt cttccccctg 420
gcaccctcct ccaagagcac ctctgggggc acagcggccc tgggctgcct ggtcaaggac 480
tacttccccg aaccggtgac ggtgtcgtgg aactcaggcg ccctgaccag cggcgtgcac 540
accttcccgg ctgtcctaca gtcctcagga ctctactccc tcagcagcgt ggtgaccgtg 600
ccctccagca gcttgggcac ccagacctac atctgcaacg tgaatcacaa gcccagcaac 660
accaaggtgg acaagaaagt tgggcccaaa tcttgtgaca aaactagtgg ccaggccggc 720


<210> 38
<211> 651
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M922 light
      chain

<400> 38
cagtctgtgc tgactcagcc accctcagcg tctgggaccc ccgggcagag ggtcaccatc 60
tcttgttctg gaagcagctc caacatcgga agtaatactg taaactggta ccagcagctc 120
ccaggaacgg cccccaaact cctcatctat agtaataatc agcggccctc aggggtccct 180
gaccgattct ctggctccaa gtctggcacc tcagcctccc tggccatcag tgggctccag 240
tctgaggatg aggctgatta ttactgtgca gcatgggatg acagcctgaa tggtcgcgtg 300
gtattcggcg gagggaccaa gctgaccgtc ctaggtcagc ccaaggctgc cccctcggtc 360
actctgttcc caccctcctc tgaggagctt caagccaaca aggccacact ggtgtgtctc 420
ataagtgact tctacccggg agccgtgaca gtggcctgga aggcagatag cagccccgtc 480
aaggcgggag tggagaccac cacaccctcc aaacaaagca acaacaagta cgcggccagc 540
agctacctga gcctgacgcc tgagcagtgg aagtcccaca aaagctacag ctgccaggtc 600
acgcatgaag ggagcaccgt ggagaagaca gtggccccta cagaatgttc a          651

<210> 39
<211> 701
<212> DNA
<213> Artificial Sequence

<220> 
<223> synthetic anti-DR4 monoclonal antibody M922 heavy
      chain

<400> 39
caggtacagc tgcagcagtc aggtccagga ctggtgaagc cctcgcagac cctctcactc 60
acctgtgcca tctccgggga cagtgtctct agcaacagtg ctgcttggaa ctggatcagg 120
cagtccccat cgagaggcct tgagtggctg ggaaggacat actacaggtc caagtggtat 180
aatgattatg cagtatctgt gaaaagtcga ataaccatca acccagacac atccaagaac 240
cagttctccc tgcagctgaa ctctgtgact cccgaggaca cggctgtgta ttactgtgca 300
agagaaacag tggctgttga tgcttttgat atctggggcc aagggacaat ggtcaccgtc 360
tcttcagcct ccaccaaggg cccatcggtc ttccccctgg caccctcctc caagagcacc 420
tctgggggca cagcggccct gggctgcctg gtcaaggact acttccccga accggtgacg 480
gtgtcgtgga actcaggcgc cctgaccagc ggcgtgcaca ccttcccggc tgtcctacag 540
tcctcaggac tctactccct cagcagcgtg gtgaccgtgc cctccagcag cttgggcacc 600
cagacctaca tctgcagcgt gaatcacaag cccagcaaca ccaaggtgga caagaaagtt 660
gagcccaaat cttgtgacaa aactagtggc caggccggcc a                     701

<210> 40
<211> 4
<212> PRT
<213> Artificial Sequence

<220> 
<223> synthetic peptide linker

<400> 40
Gly Gly Gly Ser
 1              

